You just read:

Global Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight 2016: One of Roche's Three Her2+ Breast Cancer Drugs, Recorded a 15% Sales Increase in the US and a 10% Rise Overall - Research and Markets

News provided by

Research and Markets

21 Oct, 2016, 15:10 ET